Description

All-Trans Retinoic Acid (ATRA) Capsules, also known as tretinoin capsules, are a cornerstone therapy in the management of acute promyelocytic leukemia (APL). ATRA is a retinoid that targets the specific genetic abnormality (PML-RARA fusion gene) associated with APL.

🔬 Mechanism of Action

ATRA binds to retinoic acid receptors (RARs), correcting the abnormal maturation process of promyelocytes. As a result, it induces differentiation of leukemic cells into mature granulocytes rather than directly killing them. Therefore, it plays a unique and highly effective role in APL treatment.

💊 Indications

ATRA Capsules are indicated for:

• Acute Promyelocytic Leukemia (APL)
• Newly diagnosed APL in combination with chemotherapy or arsenic trioxide
• Relapsed or refractory APL (as part of combination regimens)

📌 Key Features of All-Trans Retinoic Acid CA ATRA 10 mg

• Dosage Form: Oral capsule
• Therapeutic Class: Retinoid / Differentiation Agent
• Administration: Taken orally as prescribed by a hematologist
• Typically used in combination therapy protocols
• Requires close monitoring during treatment

⚕️ Benefits of All-Trans Retinoic Acid CA ATRA 10 mg

• High remission rates in APL patients
• Targets the underlying molecular abnormality
• Essential component of modern APL treatment protocols

⚠️ Precautions

• Risk of differentiation syndrome (APL differentiation syndrome)
• May cause headache, dry skin, elevated liver enzymes, and hyperlipidemia
• Strict monitoring of blood counts and liver function required
• Highly teratogenic — contraindicated in pregnancy
• Use only under specialist supervision

All-Trans Retinoic Acid (ATRA) Capsules 10 mg are a life-saving therapy in acute promyelocytic leukemia, offering targeted differentiation treatment and significantly improving survival outcomes when administered under expert hematology care.